Más Dermatología, n.º 41

Más Dermatol. 2023;41:27-29 doi:10.5538/1887-5181.2023.41.27 29 AVANCES Y NOVEDADES Avances y novedades en el tratamiento de la dermatitis atópica Tous Romero F 3. Reich K, Kabashima K, Peris K, Silverberg JI, Eichenfield LF, Bieber T, et al. Efficacy and safety of baricitinib combined with topical corticosteroids for treatment of moderate to severe atopic dermatitis: a randomized clinical trial. JAMA Dermatol. 2020;156(12):1333-43. 4. Guttman-Yassky E, Teixeira HD, Simpson EL, Papp KA, Pangan AL, Blauvelt A, et al. Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double-blind, randomised controlled phase 3 trials. Lancet. 2021;397(10290):2151-68. 5. Freitas E, Guttman-Yassky E, Torres T. Tralokinumab for the treatment of atopic dermatitis. Am J Clin Dermatol. 2021;22(5):625-38.

RkJQdWJsaXNoZXIy MTAyMDQzMg==